Seattle Genetics

Description

• Seattle Genetics, co-founded by Clay Siegall, is a biotechnology company leading the field of antibody-drug conjugates (ADCs) for the treatment of cancer. Our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. Our lead program, ADCETRIS® (brentuximab vedotin), is the first in a new class of ADCs. In collaboration with Takeda Pharmaceutical Company Limited, it is approved in more than 60 countries. To further expand the ADCETRIS opportunity, we are conducting a broad clinical development program evaluating its potential to become the foundation of treatment for CD30-expressing lymphomas.We also are advancing vadastuximab talirine (SGN-CD33A; 33A), a novel ADC that is expected to advance into a phase 3 trial for acute myeloid leukemia (AML) in 2016. AML is a significant unmet need, as patient outcomes have not meaningfully changed in more than 30 years.ADCETRIS and 33A are two of more than 20 ADCs in clinical development using our proprietary technology, including more than 12 internal clinical and preclinical programs. We are advancing a deep product pipeline with opportunities across hematologic malignancies and solid tumors.Our ADC technology also is employed by collaborators who are advancing multiple programs using Seattle Genetics proprietary approach to empowering antibodies. Through internal research and development, collaborations and scientific innovation, we are committed to improving treatment outcomes for patients.Seattle Genetics was founded in 1998 and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and is traded on the Nasdaq Stock Market under the symbol SGEN. We have more than 800 employees, all with a passion for helping people living with cancer.
• 

  Headquarters:21823 30th Drive Southeast , Bothell, Washington, United States

  More
• 

  Phone Number: +1 425-527-2298

• 

  Website: https://www.seattlegenetics.com

• 

  Employees:820

• 

  Revenue:> $1B

• 

  Legal Name:Seattle Genetics

• Seattle Genetics's Social Media

  
• Is this data correct?

• |  NAICS Code: 541713  |

    NYSE: SGEN

  Show More